Want to see ZBIO full AI Analyst Report?
ZBIO Stock Chart & Stats
$30.39
-$0.60(-1.94%)
At close: 4:00 PM EDT
$30.39
-$0.60(-1.94%)
Day’s Range― - ―
52-Week Range$13.50 - $44.60
Previous CloseN/A
Volume558.98K
Average Volume (3M)1.03M
Market Cap
$1.98B
Enterprise Value$680.97M
Total Cash (Recent Filing)$717.21M
Total Debt (Recent Filing)$351.73M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 18, 2026EPS Estimate
-1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.10
Shares Outstanding63,133,377
10 Day Avg. Volume846,352
30 Day Avg. Volume1,025,017
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)6.71
Price to Sales (P/S)162.41
P/FCF Ratio-9.42
Enterprise Value/Market Cap0.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.56
Enterprise Value/Ebitda-1.67
Forecast
1Y Price Target
$41.40Price Target Upside36.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.81
Revenue Forecast (FY)$30.22M
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayLarge financing and reported $718M of cash/investments materially extend runway into 2029, supporting multi-year execution of late-stage trials and potential regulatory filings. This reduces near-term financing pressure, allowing focus on clinical milestones and commercialization planning.
Positive Phase 3 EfficacyRobust 56% flare-risk reduction in Phase 3 is a durable clinical outcome that enhances the asset's regulatory and commercial prospects. A clear positive pivotal result strengthens the case for submission, label differentiation, and long-term franchise value if approvals follow.
Improved Balance Sheet EquityShift from negative to positive equity signals improved capitalization and investor support. Stronger book equity provides a more stable financing base and better creditor perception, enhancing the firm's ability to fund R&D and pursue commercial scale-up over the medium term.
Bears Say
High Cash BurnConsistent ~ $210M TTM operating cash outflow reflects structural cash consumption to fund trials and operations. Even with current liquidity, sustained burn requires continued financing or rapid revenue generation; prolonged deficits raise dilution and financing-risk over the medium term.
Very Limited Revenue BaseMinimal, volatile $10M TTM revenue and widening losses indicate the company remains pre-commercial and dependent on pipeline success. Lack of recurring sales undermines self-funding ability and leaves operations exposed to clinical/regulatory setbacks over the coming months.
Rising Debt And LeverageRapid increase in debt to ~$195M materially raises leverage and fixed obligations. Higher leverage limits financial flexibility, increases interest and covenant risk, and makes the firm more vulnerable to prolonged losses or delayed approvals during the medium-term development cycle.
Zenas BioPharma, Inc. News
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $13.50 and its highest was $44.60 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $1.98B.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
Zenas BioPharma, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 15 days.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on May 13, 2026. The company reported -$1.46 earnings per share for the quarter, beating the consensus estimate of -$1.474 by $0.014.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate is -1.12.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 63,133,377 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$1.46 in its last earnings report, beating expectations of -$1.474. Following the earnings report the stock price went up 4.019%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zenas BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.40 (36.23% Upside)
$41.40 (36.23% Upside)
Blogger Sentiment
Bullish
ZBIO Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 740.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
124.01%
Trailing 12-Months
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
ZBIO Stock 12 Month Forecast
Average Price Target
$41.40
▲(36.23% Upside)
Technical Analysis
Ownership Overview
25.17% Insiders
22.69% Mutual Funds
0.47% Other Institutional Investors
43.47% Public Companies and Individual Investors